Rapid Micro Biosystems IncNASDAQ:RPIDNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.8710
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.8205/ 1
- Ask / Lots0.9800/ 23
- Open / Previous Close0.0000 / 0.8710
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RPID |
|---|---|---|
| 10:15 ET | 202 | 0.89 |
| 12:05 ET | 4940 | 0.886 |
| 12:07 ET | 5000 | 0.9199 |
| 01:01 ET | 100 | 0.9199 |
| 02:06 ET | 100 | 0.8859 |
| 03:00 ET | 112 | 0.871 |
Apr 18, 2024
Rapid Micro Biosystems to Announce First Quarter 2024 Financial Results on May 3, 2024, from 4:30PM ET on Thursday Apr 18, 2024 by Dow Jones
4:30PM ET on Thursday Apr 18, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Rapid Micro Biosystems Inc | 32.6M | -0.7x | --- |
Ocuphire Pharma Inc | 37.5M | -3.2x | --- |
Cyanotech Corp | 2.1M | -0.4x | --- |
cbdMD Inc | 3.0M | 0.0x | --- |
Sunshine Biopharma Inc | 1.4M | -0.1x | --- |
Gelesis Holdings Inc | 1.5M | 0.0x | --- |
Company Information
Rapid Micro Biosystems, Inc. is a life sciences technology company providing mission critical automation solutions to facilitate the manufacturing and release of healthcare products, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company's flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control, testing workflows used in pharmaceutical manufacturing operations. It offers four specific applications for testing of microbial contamination: Environmental Monitoring, which tests the manufacturing environment, including circulating air, exposed surfaces, and personnel; Water, which tests any purified water used at any stage of the drug production process, including water for injection; In-Process Bioburden, which tests raw materials, drug substance and in-process product, and Sterility Release offering final testing of finished product to ensure sterility before the product is released for commercial sale.
Contact Information
- Headquarters
- 1001 Pawtucket Blvd.LOWELL, MA, United States 01854
- Phone
- 978-349-3200
- Fax
- 302-636-5401
Executives
- Independent Chairman of the Board
- Kirk Malloy
- President, Chief Executive Officer, Director
- Robert Spignesi
- Chief Financial Officer
- Sean Wirtjes
- Chief Operating Officer
- John Wilson
- Chief Human Resource Officer
- Victoria Vezina
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $32.6M |
|---|---|
Revenue (TTM) | $22.5M |
Shares Outstanding | 37.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.22 |
Book Value | $2.78 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | 1.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -251.18% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
